Fluorescent cystoscopyand transurethral electroresection in diagnosis and treatment ofpatients with invasive cancer of the urinary bladder


Cite item

Full Text

Abstract

From 1996 to 2002 we examined and treated 224 patients with
invasive cancer of the urinary bladder (ICUB). The examination
complex included clinical, laboratory, radiation tests, endoscopic and
morphological investigations of the surgical material. The patients received
four types of treatment: transurethral resection (TUR) of the
bladder wall (n = 102) alone; TUR+MVAC chemotherapy (n = 56);
open resection of the urinary bladder only (n = 38); open resection+MVAC
chemotherapy (n = 28). In diagnosis of papillary lesions
sensitivity of cystoscopy (CS) was 66.6%, fluorescent CS (FCS) -95.2%.
Sensitivity in diagnosis of squamous tumors was 33.3 and
91.6%, respectively. The best results were achieved in patients with
pT2A tumor invasion depth, Gl differentiation of tumor cells after
TUR with adjuvant polychemotherapy (PCT) recurrences in these
patients arose by 41.2% less frequently than in patients after TUR only,
5-year survival in patients after TUR+PCT was 83.3%. Thus, FCS
improves diagnosis of urinary bladder tumors (sensitivity of CS was
70.0% vs that of FCS - 95.0%). In cancer of the urinary bladder the
organ can be saved only at stage pT2Gl. A method of choice is TUR
of the bladder wall with adjuvant PCT.
Key words: cancer of the urinary bladder, fluorescent cystoscopy,
transurethral electroresection of the urinary bladder, open resection
of the urinary bladder

References

  1. Skinner D. G., Studer U. E., Okada К. et al. Which patients are suitable for continent diversion or bladder substitution following cystectomy or other definitive local treatment? Int. J. Urol. 1995; 2 (suppl2): 105-122.
  2. Holmang S., Hedelin В., Anderstrom C., Johansson S. L. The relationship among multiple recurrences progression and prognosis of patients with stage Та and Tl transitional cell cancer of the bladder followed for at least 20 years. J. Urol. (Baltimore) 1995; 153: 1823-1827.
  3. Kurth K. H., Denis L., Bouffioux С. Н. et al. Factors affecting recurrence and progression is superficial bladder tumors. Eur.J. Cancer 1995; 31: 1840-1846.
  4. Лопаткин H. А., Камалов А. А., Кудрявцев Ю. В., ТокаревВ. Ф. Урология 2000; 4: 3-6.
  5. Moore M. J., О 'Sullivan В., Tannock I. F. How physician would wish to be treated if they had genitourinary cancer. J. Clin. Oncol. 1988; 1736: 1736-1745.
  6. Frieha F., Reese J., Torti F. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, metothrexate and vinblastine chemotherapy for muscle invasive bladder can-cer. J. Urol. (Baltimore) 1996; 155: 495-500.
  7. Tester W., Porter A., Asbell S. et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: result of RTOG protocol 85-12. Int. Radiat. Oncol. Biol. Phys. 1993; 25: 783-790.
  8. Лопаткин Н. А., Мартов А. Г., Даренков С. П. и др. Оперативное лечение опухолей мочевого пузыря. Урол. и нефрол. 1999; 1: 26-31.
  9. Матвеев Б. П., Фигурин К. М. Результаты оперативного лечения больных раком мочевого пузыря. Урол. и нефрол. 1997; 2: 25-28.
  10. Хомяков Б. К., Новиков А. И., Новиков П. Б., Шрисов Ш. Н. Возможности трансуретральной электрорезекции при инвазивном раке мочевого пузыря. В кн: Рак мочевого пузыря: Материалы конференции. Ростов-н/Д; 1998. 46-47.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2004 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies